Mechanisms of action of fluvoxamine for COVID-19: a historical review

{ 'indexed': {'date-parts': [[2022, 1, 8]], 'date-time': '2022-01-08T05:51:27Z', 'timestamp': 1641621087099}, 'reference-count': 125, 'publisher': 'Springer Science and Business Media LLC', 'license': [ { 'start': { 'date-parts': [[2022, 1, 7]], 'date-time': '2022-01-07T00:00:00Z', 'timestamp': 1641513600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}, { 'start': { 'date-parts': [[2022, 1, 7]], 'date-time': '2022-01-07T00:00:00Z', 'timestamp': 1641513600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'short-container-title': ['Mol Psychiatry'], 'DOI': '10.1038/s41380-021-01432-3', 'type': 'journal-article', 'created': {'date-parts': [[2022, 1, 7]], 'date-time': '2022-01-07T10:02:49Z', 'timestamp': 1641549769000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': ['Mechanisms of action of fluvoxamine for COVID-19: a historical review'], 'prefix': '10.1038', 'author': [ {'given': 'Yaeko', 'family': 'Hashimoto', 'sequence': 'first', 'affiliation': []}, {'given': 'Takuji', 'family': 'Suzuki', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-8892-0439', 'authenticated-orcid': False, 'given': 'Kenji', 'family': 'Hashimoto', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2022, 1, 7]]}, 'reference': [ { 'key': '1432_CR1', 'doi-asserted-by': 'crossref', 'first-page': '405', 'DOI': '10.1016/j.healun.2020.03.012', 'volume': '39', 'author': 'HK Siddiqi', 'year': '2020', 'unstructured': 'Siddiqi HK, Mehra MR. COVID-19 illness in naïve and immunosuppressed ' 'states: a clinical-therapeutic staging proposal. J Heart Lung Transpl. ' '2020;39:405–7.', 'journal-title': 'J Heart Lung Transpl'}, { 'key': '1432_CR2', 'doi-asserted-by': 'crossref', 'first-page': '18', 'DOI': '10.1016/j.bbi.2020.03.031', 'volume': '87', 'author': 'Y Wu', 'year': '2020', 'unstructured': 'Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system ' 'involvement after infection with COVID-19 and other coronaviruses. Brain ' 'Behav Immun. 2020;87:18–22.', 'journal-title': 'Brain Behav Immun'}, { 'key': '1432_CR3', 'doi-asserted-by': 'crossref', 'first-page': '916', 'DOI': '10.1016/j.bbi.2020.03.007', 'volume': '88', 'author': 'Z Li', 'year': '2020', 'unstructured': 'Li Z, Ge J, Yang M, Feng J, Qiao M, Jiang R, et al. Vicarious ' 'traumatization in the general public, members, and non-members of ' 'medical teams aiding in COVID-19 control. Brain Behav immun. ' '2020;88:916–9.', 'journal-title': 'Brain Behav immun'}, { 'key': '1432_CR4', 'doi-asserted-by': 'crossref', 'first-page': '50', 'DOI': '10.1016/j.bbi.2020.05.075', 'volume': '88', 'author': 'J Zhang', 'year': '2020', 'unstructured': 'Zhang J, Xu D, Xie B, Zhang Y, Huang H, Liu H, et al. Poor-sleep is ' 'associated with slow recovery from lymphopenia and an increased need for ' 'ICU care in hospitalized patients with COVID-19: A retrospective cohort ' 'study. Brain Behav Immun. 2020;88:50–8.', 'journal-title': 'Brain Behav Immun'}, { 'key': '1432_CR5', 'doi-asserted-by': 'crossref', 'first-page': '4982', 'DOI': '10.1038/s41380-021-01036-x', 'volume': '26', 'author': 'K Yuan', 'year': '2021', 'unstructured': 'Yuan K, Gong YM, Liu L, Sun YK, Tian SS, Wang YJ, et al. Prevalence of ' 'posttraumatic stress disorder after infectious disease pandemics in the ' 'twenty-first century, including COVID-19: a meta-analysis and systematic ' 'review. Mol Psychiatry. 2021;26:4982–98.', 'journal-title': 'Mol Psychiatry'}, { 'key': '1432_CR6', 'doi-asserted-by': 'crossref', 'first-page': '8790', 'DOI': '10.3390/ijerph18168790', 'volume': '18', 'author': 'L Shi', 'year': '2021', 'unstructured': 'Shi L, Lu ZA, Que JY, Huang XL, Lu QD, Liu L, et al. Long-term impact of ' 'COVID-19 on mental health among the general public: a nationwide ' 'longitudinal study in China. Int J Environ Res Public Health. ' '2021;18:8790.', 'journal-title': 'Int J Environ Res Public Health'}, { 'key': '1432_CR7', 'doi-asserted-by': 'crossref', 'first-page': '249', 'DOI': '10.1007/s00406-020-01231-x', 'volume': '271', 'author': 'K Hashimoto', 'year': '2021', 'unstructured': 'Hashimoto K. Repurposing of CNS drugs to treat COVID-19 infection: ' 'targeting the sigma-1 receptor. Eur Arch psychiatry Clin Neurosci. ' '2021;271:249–58.', 'journal-title': 'Eur Arch psychiatry Clin Neurosci'}, { 'key': '1432_CR8', 'doi-asserted-by': 'crossref', 'first-page': 'e2000115.', 'DOI': '10.1002/minf.202000115', 'volume': '40', 'author': 'CN Cavasotto', 'year': '2021', 'unstructured': 'Cavasotto CN, Di Filippo JI. In silico drug repurposing for COVID-19: ' 'targeting SARS-CoV-2 proteins through docking and consensus ranking.Mol ' 'Inform. 2021;40:e2000115.', 'journal-title': 'Mol Inform'}, { 'key': '1432_CR9', 'doi-asserted-by': 'crossref', 'first-page': '107930', 'DOI': '10.1016/j.pharmthera.2021.107930', 'volume': '228', 'author': 'YL Ng', 'year': '2021', 'unstructured': 'Ng YL, Salim CK, Chu JJH. Drug repurposing for COVID-19: approaches, ' 'challenges and promising candidates. Pharm Ther. 2021;228:107930.', 'journal-title': 'Pharm Ther'}, { 'key': '1432_CR10', 'doi-asserted-by': 'crossref', 'first-page': 'e63', 'DOI': '10.1016/S2213-2600(21)00270-8', 'volume': '9', 'author': 'P Venkatesan', 'year': '2021', 'unstructured': 'Venkatesan P. Repurposing drugs for treatment of COVID-19. Lancet Respir ' 'Med. 2021;9:e63.', 'journal-title': 'Lancet Respir Med'}, { 'key': '1432_CR11', 'doi-asserted-by': 'crossref', 'first-page': '59', 'DOI': '10.1016/j.bbi.2020.04.046', 'volume': '87', 'author': 'J Zhang', 'year': '2020', 'unstructured': 'Zhang J, Xie B, Hashimoto K. Current status of potential therapeutic ' 'candidates for the COVID-19 crisis. Brain Behav Immun. 2020;87:59–73.', 'journal-title': 'Brain Behav Immun'}, { 'key': '1432_CR12', 'doi-asserted-by': 'crossref', 'first-page': '541', 'DOI': '10.1126/science.abi4708', 'volume': '373', 'author': 'TA Tummino', 'year': '2021', 'unstructured': 'Tummino TA, Rezelj VV, Fischer B, Fischer A, O’Meara MJ, Monel B, et al. ' 'Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2. ' 'Science. 2021;373:541–7.', 'journal-title': 'Science'}, { 'key': '1432_CR13', 'doi-asserted-by': 'crossref', 'first-page': '100121.', 'DOI': '10.1016/j.metop.2021.100121', 'volume': '12', 'author': 'K Srivastava', 'year': '2021', 'unstructured': 'Srivastava K, Singh MK. Drug repurposing in COVID-19: a review with ' 'past, present and future. Metab Open. 2021;12:100121.', 'journal-title': 'Metab Open'}, { 'key': '1432_CR14', 'doi-asserted-by': 'crossref', 'first-page': '2165', 'DOI': '10.1001/jama.2020.22240', 'volume': '324', 'author': 'WH Self', 'year': '2020', 'unstructured': 'Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, et al. ' 'Effect of hydroxychloroquine on clinical status at 14 days in ' 'hospitalized patients with COVID-19: a randomized clinical trial. JAMA. ' '2020;324:2165–76.', 'journal-title': 'JAMA'}, { 'key': '1432_CR15', 'doi-asserted-by': 'crossref', 'first-page': '417', 'DOI': '10.1056/NEJMoa2021801', 'volume': '384', 'author': 'O Mitjà', 'year': '2021', 'unstructured': 'Mitjà O, Corbacho-Monné M, Ubals M, Alemany A, Suñer C, Tebé C, et al. A ' 'cluster-randomized trial of hydroxychloroquine for prevention of ' 'Covid-19. N Eng J Med. 2021;384:417–27.', 'journal-title': 'N Eng J Med'}, { 'key': '1432_CR16', 'doi-asserted-by': 'crossref', 'first-page': 'e216468', 'DOI': '10.1001/jamanetworkopen.2021.6468', 'volume': '4', 'author': 'G Reis', 'year': '2021', 'unstructured': 'Reis G, Moreira Silva EADS, Medeiros Silva DC, Thabane L, Singh G, Park ' 'JJH, et al. Effect of early treatment with hydroxychloroquine or ' 'lopinavir and ritonavir on risk of hospitalization among patients with ' 'COVID-19: the TOGETHER randomized clinical trial. JAMA Netw Open. ' '2021;4:e216468.', 'journal-title': 'JAMA Netw Open'}, { 'key': '1432_CR17', 'doi-asserted-by': 'crossref', 'first-page': '1426', 'DOI': '10.1001/jama.2021.3071', 'volume': '325', 'author': 'E López-Medina', 'year': '2021', 'unstructured': 'López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, ' 'et al. Effect of ivermectin on time to resolution of symptoms among ' 'adults with mild COVID-19: a randomized clinical trial. JAMA. ' '2021;325:1426–35.', 'journal-title': 'JAMA'}, { 'key': '1432_CR18', 'doi-asserted-by': 'crossref', 'first-page': '1473', 'DOI': '10.1007/s43440-021-00245-z', 'volume': '73', 'author': 'CS Kow', 'year': '2021', 'unstructured': 'Kow CS, Merchant HA, Mustafa ZU, Hasan SS. The association between the ' 'use of ivermectin and mortality in patients with COVID-19: a ' 'meta-analysis. Pharm Rep. 2021;73:1473–9.', 'journal-title': 'Pharm Rep.'}, { 'key': '1432_CR19', 'doi-asserted-by': 'crossref', 'unstructured': 'Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. ' 'Ivermectin for the treatment of COVID-19: a systematic review and ' 'meta-analysis of randomized controlled trials. Clin Infect Dis. 2021. ' 'ciab591.', 'DOI': '10.1101/2021.05.21.21257595'}, { 'key': '1432_CR20', 'doi-asserted-by': 'crossref', 'first-page': '2292', 'DOI': '10.1001/jama.2020.22760', 'volume': '324', 'author': 'E Lenze', 'year': '2020', 'unstructured': 'Lenze E, Mattar C, Zorumski CF, Zorumski CF, Stevens A, Schweiger J, et ' 'al. Fluvoxamine vs placebo and clinical deterioration in outpatients ' 'with symptomatic COVID-19. A randomized clinical trial. JAMA. ' '2020;324:2292–300.', 'journal-title': 'JAMA'}, { 'key': '1432_CR21', 'doi-asserted-by': 'crossref', 'first-page': '5199', 'DOI': '10.1038/s41380-021-01021-4', 'volume': '26', 'author': 'N Hoertel', 'year': '2021', 'unstructured': 'Hoertel N, Sánchez-Rico M, Vernet R, Beeker N, Jannot AS, Neuraz A, et ' 'al. Association between antidepressant use and reduced risk of ' 'intubation or death in hospitalized patients with COVID-19: results from ' 'an observational study. Mol Psychiatry. 2021;26:5199–212.', 'journal-title': 'Mol Psychiatry'}, { 'key': '1432_CR22', 'doi-asserted-by': 'publisher', 'unstructured': 'Hashimoto Y, Suzuki T, Hashimoto K. Old drug fluvoxamine, new hope for ' 'COVID-19. Eur Arch Psychiatry Clin Neurosci. 2021. ' 'https://doi.org/10.1007/s00406-021-01326-z.', 'DOI': '10.1007/s00406-021-01326-z'}, { 'key': '1432_CR23', 'doi-asserted-by': 'crossref', 'first-page': 'ofab050', 'DOI': '10.1093/ofid/ofab050', 'volume': '8', 'author': 'D Seftel', 'year': '2021', 'unstructured': 'Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early ' 'treatment of coronavirus disease 19. Open Forum Infect Dis. ' '2021;8:ofab050.', 'journal-title': 'Open Forum Infect Dis'}, { 'key': '1432_CR24', 'doi-asserted-by': 'publisher', 'author': 'G Reis', 'year': '2021', 'unstructured': 'Reis G, Moreira Silva EADS, Medeiros Silva DC, Thabane L, Milagres AC, ' 'Ferreira TS, et al. Effect of early treatment with fluvoxamine on risk ' 'of emergency care and hospitalization among patients with COVID-19: the ' 'TOGETHER randomized, platform clinical trial. Lancet Glob Health. 2021. ' 'https://doi.org/10.1016/S2214-109X(21)00448-4.', 'journal-title': 'Lancet Glob Health', 'DOI': '10.1016/S2214-109X(21)00448-4'}, { 'key': '1432_CR25', 'unstructured': 'Sax PE. Could this be our first effective, inexpensive, widely available ' 'outpatient treatment for COVID-19? NEJM J Watch. 2021. ' 'https://blogs.jwatch.org/hiv-id-observations/index.php/could-this-be-our-first-effective-inexpensive-widely-available-outpatient-treatEl-battrawy.Iment-for-covid-19/2021/08/12/.'}, { 'key': '1432_CR26', 'doi-asserted-by': 'publisher', 'author': 'M Calusic', 'year': '2021', 'unstructured': 'Calusic M, Marcec R, Luksa L, Jurkovic I, Kovac N, Mihaljevic S, et al. ' 'Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open ' 'label, prospective cohort trial with matched controls. Bri J Clin Pharm. ' '2021. https://doi.org/10.1111/bcp.15126.', 'journal-title': 'Bri J Clin Pharm', 'DOI': '10.1111/bcp.15126'}, { 'key': '1432_CR27', 'doi-asserted-by': 'crossref', 'first-page': 'e2133090', 'DOI': '10.1001/jamanetworkopen.2021.33090', 'volume': '4', 'author': 'T Oskotsky', 'year': '2021', 'unstructured': 'Oskotsky T, Maric I, Tang A, Oskotsky B, Wong RJ, Aghaeepour N, et al. ' 'Mortality risk among patients with COVID-19 prescribed selective ' 'serotonin reuptake inhibitor antidepressants. JAMA Netw Open. ' '2021;4:e2133090.', 'journal-title': 'JAMA Netw Open'}, { 'key': '1432_CR28', 'doi-asserted-by': 'publisher', 'author': 'L Fei', 'year': '2021', 'unstructured': 'Fei L, Santarelli G, D’Anna G, Moretti S, Mirossi G, Patti A, et al. Can ' 'SSRI/SNRI antidepressants decrease the ‘cytokine storm’ in the course of ' 'COVID-19 pneumonia? Panminerva Med. 2021. ' 'https://doi.org/10.23736/S0031-0808.21.04436-0.', 'journal-title': 'Panminerva Med', 'DOI': '10.23736/S0031-0808.21.04436-0.'}, { 'key': '1432_CR29', 'doi-asserted-by': 'crossref', 'first-page': '797', 'DOI': '10.1016/S2215-0366(21)00232-7', 'volume': '8', 'author': 'B Vai', 'year': '2021', 'unstructured': 'Vai B, Mazza MG, Delli Colli C, Foiselle M, Allen B, Benedetti F, et al. ' 'Mental disorders and risk of COVID-19-related mortality, ' 'hospitalization, and intensive care unit admission: a systematic review ' 'and meta-analysis. Lancet Psychiatry. 2021;8:797–812.', 'journal-title': 'Lancet Psychiatry'}, { 'key': '1432_CR30', 'doi-asserted-by': 'crossref', 'first-page': 'e13582.', 'DOI': '10.1111/eci.13582', 'volume': '51', 'author': 'I El-Battrawy', 'year': '2021', 'unstructured': 'El-Battrawy I, Nuñez-Gil IJ, Abumayyaleh M, Estrada V, Manuel ' 'Becerra-Muñoz V, Uribarri A, et al. COVID-19 and the impact of arterial ' 'hypertension- An analysis of the international HOPE COVID-19 Registry ' '(Italy-Spain-Germany). Eur J Clin Invest. 2021;51:e13582.', 'journal-title': 'Eur J Clin Invest'}, { 'key': '1432_CR31', 'doi-asserted-by': 'crossref', 'first-page': 'e0247122', 'DOI': '10.1371/journal.pone.0247122', 'volume': '16', 'author': 'N Hoertel', 'year': '2021', 'unstructured': 'Hoertel N, Sánchez-Rico M, Vernet R, Jannot AS, Neuraz A, Blanco C, et ' 'al. Observational study of haloperidol in hospitalized patients with ' 'COVID-19. PLoS ONE. 2021;16:e0247122.', 'journal-title': 'PLoS ONE'}, { 'key': '1432_CR32', 'doi-asserted-by': 'crossref', 'first-page': '221', 'DOI': '10.1007/s40261-021-01001-0', 'volume': '41', 'author': 'N Hoertel', 'year': '2021', 'unstructured': 'Hoertel N, Sánchez-Rico M, Vernet R, Jannot AS, Neuraz A, Blanco C, et ' 'al. Observational study of chlorpromazine in hospitalized patients with ' 'COVID-19. Clin Drug Invest. 2021;41:221–33.', 'journal-title': 'Clin Drug Invest'}, { 'key': '1432_CR33', 'doi-asserted-by': 'crossref', 'first-page': '5618', 'DOI': '10.1073/pnas.81.17.5618', 'volume': '81', 'author': 'SW Tam', 'year': '1984', 'unstructured': 'Tam SW, Cook L. Sigma opiates and certain antipsychotic drugs mutually ' 'inhibit (+)-[3H]SKF10,047 and [3H]haloperidol binding in guinea pig ' 'brain membranes. Proc Natl Acad Sci USA. 1984;81:5618–21.', 'journal-title': 'Proc Natl Acad Sci USA'}, { 'key': '1432_CR34', 'doi-asserted-by': 'crossref', 'first-page': '295', 'DOI': '10.1016/0014-2999(90)90356-B', 'volume': '187', 'author': 'K Hashimoto', 'year': '1990', 'unstructured': 'Hashimoto K, Goromaru T. High-affinity binding of [3H]6-nitroquipazine ' 'to 5-hydroxytryptamine transporter in human platelets. Eur J Pharm. ' '1990;187:295–302.', 'journal-title': 'Eur J Pharm'}, { 'key': '1432_CR35', 'doi-asserted-by': 'crossref', 'first-page': '119', 'DOI': '10.1160/TH03-05-0330', 'volume': '91', 'author': 'E Maurer-Spurej', 'year': '2004', 'unstructured': 'Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective ' 'serotonin reuptake inhibitors on human platelet serotonin. Thromb ' 'Haemost. 2004;91:119–28.', 'journal-title': 'Thromb Haemost'}, { 'key': '1432_CR36', 'doi-asserted-by': 'crossref', 'first-page': '3394', 'DOI': '10.1182/blood-2011-09-336933', 'volume': '119', 'author': 'G Jedlitschky', 'year': '2012', 'unstructured': 'Jedlitschky G, Greinacher A, Kroemer HK. Transporters in human ' 'platelets: physiologic function and impact for pharmacotherapy. Blood. ' '2012;119:3394–402.', 'journal-title': 'Blood'}, { 'key': '1432_CR37', 'doi-asserted-by': 'crossref', 'first-page': '652688', 'DOI': '10.3389/fphar.2021.652688', 'volume': '12', 'author': 'VP Sukhatme', 'year': '2021', 'unstructured': 'Sukhatme VP, Reiersen AM, Vayttaden SJ, Sykhatme W. Fluvoxamine: a ' 'review of its mechanisms of actions and its role in COVID-19. Front ' 'Pharm. 2021;12:652688.', 'journal-title': 'Front Pharm'}, { 'key': '1432_CR38', 'doi-asserted-by': 'crossref', 'first-page': '469', 'DOI': '10.1016/j.bbi.2011.12.011', 'volume': '26', 'author': 'RJ Tynan', 'year': '2012', 'unstructured': 'Tynan RJ, Weidenhofer J, Hinwood M, Cairns MJ, Day TA, Walter FR. A ' 'comparative examination of the antiinflammatory effects of SSRI and SNRI ' 'antidepressants on LPS stimulated microglia. Brain Behav Immun. ' '2012;26:469–79.', 'journal-title': 'Brain Behav Immun'}, { 'key': '1432_CR39', 'doi-asserted-by': 'crossref', 'first-page': '853', 'DOI': '10.1016/j.pbb.2012.12.003', 'volume': '103', 'author': 'Y Ohgi', 'year': '2013', 'unstructured': 'Ohgi Y, Futamura T, Kikuchi T, Hashimoto K. Effects of antidepressants ' 'on alterations in serum cytokines and depressive-like behavior in mice ' 'after lipopolysaccharide administration. Pharm Biochem Behav. ' '2013;103:853–9.', 'journal-title': 'Pharm Biochem Behav'}, { 'key': '1432_CR40', 'doi-asserted-by': 'crossref', 'first-page': '7', 'DOI': '10.1016/j.pbb.2016.02.005', 'volume': '144', 'author': 'C Dong', 'year': '2016', 'unstructured': 'Dong C, Zhang JC, Yao W, Ren Q, Yang C, Ma M, et al. Effects of ' 'escitalopram, R-citalopram, and reboxetine on serum levels of tumor ' 'necrosis factor-alpha, interleukin-10, and depression-like behavior in ' 'mice after lipopolysaccharide administration. Pharm Biochem Behav. ' '2016;144:7–12.', 'journal-title': 'Pharm Biochem Behav'}, { 'key': '1432_CR41', 'doi-asserted-by': 'crossref', 'first-page': '7796', 'DOI': '10.3390/ijms16047796', 'volume': '16', 'author': 'K Hashimoto', 'year': '2015', 'unstructured': 'Hashimoto K. Inflammatory biomarkers as differential predictors of ' 'antidepressant response. Int J Mol Sci. 2015;16:7796–801.', 'journal-title': 'Int J Mol Sci'}, { 'key': '1432_CR42', 'doi-asserted-by': 'crossref', 'first-page': '24', 'DOI': '10.1016/j.bbi.2019.02.021', 'volume': '79', 'author': 'L Wang', 'year': '2019', 'unstructured': 'Wang L, Wang R, Liu L, Qiao D, Baldwin DS, Hou R. Effects of SSRIs on ' 'peripheral inflammatory markers in patients with major depressive ' 'disorder: A systematic review and meta-analysis. Brain Behav Immun. ' '2019;79:24–38.', 'journal-title': 'Brain Behav Immun'}, { 'key': '1432_CR43', 'doi-asserted-by': 'crossref', 'first-page': '189', 'DOI': '10.1016/j.bbr.2016.08.005', 'volume': '316', 'author': 'E Dallé', 'year': '2017', 'unstructured': 'Dallé E, Daniels WM, Mabandia MV. Fluvoxamine maleate normalizes ' 'striatal neuronal inflammatory cytokine activity in a Parkinsonian rat ' 'model associated with depression. Behav Brain Res. 2017;316:189–96.', 'journal-title': 'Behav Brain Res'}, { 'key': '1432_CR44', 'first-page': '977', 'volume': '19', 'author': 'L Rafiee', 'year': '2016', 'unstructured': 'Rafiee L, Hajhashemi V, Javanmard SH. Fluvoxamine inhibits some ' 'inflammatory genes expression in LPS/stimulated human endothelial cells, ' 'U937 macrophages, and carrageenan-induced paw edema in rat. Iran J Basic ' 'Med Sci. 2016;19:977–84.', 'journal-title': 'Iran J Basic Med Sci'}, { 'key': '1432_CR45', 'doi-asserted-by': 'crossref', 'DOI': '10.1038/s41598-017-04968-z', 'volume': '7', 'author': 'M Ghareghani', 'year': '2017', 'unstructured': 'Ghareghani M, Zibara K, Sadeghi H, Dokoohaki S, Sadeghi H, Aryanpour R, ' 'et al. Fluvoxamine stimulates oligodendrogenesis of cultured neural stem ' 'cells and attenuates inflammation and demyelination in an animal model ' 'of multiple sclerosis. Sci Rep. 2017;7:4923.', 'journal-title': 'Sci Rep.'}, { 'key': '1432_CR46', 'doi-asserted-by': 'crossref', 'first-page': '1679', 'DOI': '10.1016/0006-2952(91)90169-6', 'volume': '41', 'author': 'K Hashimoto', 'year': '1991', 'unstructured': 'Hashimoto K, Goromaru T. High-affinity [3H]6-nitroquipazine binding to ' 'the 5-hydroxytryptamine transport system in rat lung. Biochem Pharm. ' '1991;41:1679–82.', 'journal-title': 'Biochem Pharm'}, { 'key': '1432_CR47', 'doi-asserted-by': 'crossref', 'first-page': '587', 'DOI': '10.1016/0883-2897(87)90030-4', 'volume': '46', 'author': 'K Hashimoto', 'year': '1987', 'unstructured': 'Hashimoto K, Inoue O, Suzuki K, Yamasaki T, Kojima M. Synthesis and ' 'evaluation of [11C]cyanoimipramine. Int J Rad Appl Instrum B. ' '1987;46:587–92.', 'journal-title': 'Int J Rad Appl Instrum B'}, { 'key': '1432_CR48', 'doi-asserted-by': 'crossref', 'first-page': '1289', 'DOI': '10.1007/s00259-002-0884-4', 'volume': '29', 'author': 'A Takano', 'year': '2002', 'unstructured': 'Takano A, Suhara T, Sudo Y, Inoue M, Hashimoto K, Zhang MR, et al. ' 'Comparative evaluation of two serotonin transporter ligands in the human ' 'brain: [11C](+)McN5652 and [11C]cyanoimipramine. Eur J Nucl Med. ' '2002;29:1289–97.', 'journal-title': 'Eur J Nucl Med'}, { 'key': '1432_CR49', 'doi-asserted-by': 'crossref', 'first-page': '365', 'DOI': '10.1007/978-3-662-45805-1_15', 'volume': '218', 'author': 'S Adnot', 'year': '2013', 'unstructured': 'Adnot S, Houssaini A, Abid S, Marcos E, Amsellem V. Serotonin ' 'transporter and serotonin receptors. Handb Exp Pharm. 2013;218:365–80.', 'journal-title': 'Handb Exp Pharm'}, { 'key': '1432_CR50', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1016/j.euroneuro.2021.09.009', 'volume': '54', 'author': 'MG Mazza', 'year': '2021', 'unstructured': 'Mazza MG, Zanardi R, Palladini M, Rovere-Querini P, Benedetti F. Rapid ' 'response to selective serotonin reuptake inhibitors in post-COVID ' 'depression. Eur Neuropsychopharmacol. 2021;54:1–6.', 'journal-title': 'Eur Neuropsychopharmacol'}, { 'key': '1432_CR51', 'doi-asserted-by': 'crossref', 'first-page': '6377', 'DOI': '10.1128/JVI.03557-12', 'volume': '87', 'author': 'M Friesland', 'year': '2013', 'unstructured': 'Friesland M, Mingorance L, Chung J, Chisari FV, Gastaminza P. Sigma-1 ' 'receptor regulates early steps of viral RNA replication at the inset of ' 'hepatitis C virus infection. J Virol. 2013;87:6377–90.', 'journal-title': 'J Virol'}, { 'key': '1432_CR52', 'doi-asserted-by': 'crossref', 'first-page': '100', 'DOI': '10.1016/j.virusres.2015.03.013', 'volume': '209', 'author': 'C Vasallo', 'year': '2015', 'unstructured': 'Vasallo C, Gastaminza P. Cellular stress response in hepatitis C virus ' 'infection: mastering a two-edged sword. Virus Res. 2015;209:100–17.', 'journal-title': 'Virus Res'}, { 'key': '1432_CR53', 'doi-asserted-by': 'crossref', 'first-page': '459', 'DOI': '10.1038/s41586-020-2286-9', 'volume': '583', 'author': 'DE Gordon', 'year': '2020', 'unstructured': 'Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A ' 'SARS-CoV-2 protein interaction map reveals targets for drug repurposing. ' 'Nature. 2020;583:459–68.', 'journal-title': 'Nature'}, { 'key': '1432_CR54', 'doi-asserted-by': 'crossref', 'first-page': 'eabe9403.', 'DOI': '10.1126/science.abe9403', 'volume': '370', 'author': 'DE Gordon', 'year': '2020', 'unstructured': 'Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S, Braberg H, et al. ' 'Comparative host-coronavirus protein interaction networks reveal ' 'pan-viral disease mechanisms. Science. 2020;370:eabe9403.', 'journal-title': 'Science'}, { 'key': '1432_CR55', 'doi-asserted-by': 'crossref', 'first-page': '582310', 'DOI': '10.3389/fphar.2020.582310', 'volume': '11', 'author': 'JM Vela', 'year': '2020', 'unstructured': 'Vela JM. Repurposing sigma-1 receptor ligands for COVID-19 therapy? ' 'Front Pharm. 2020;11:582310.', 'journal-title': 'Front Pharm'}, { 'key': '1432_CR56', 'doi-asserted-by': 'crossref', 'first-page': '435', 'DOI': '10.1080/14728222.2021.1952987', 'volume': '25', 'author': 'JM Brimson', 'year': '2021', 'unstructured': 'Brimson JM, Prasanth MI, Malar DS, Brimson S, Thitilertdecha P, ' 'Tencomnao T. Drugs that offer the potential to reduce hospitalization ' 'and mortality from SARS-CoV-2 infection: the possible role of the ' 'sigma-1 receptor and autophagy. Expert Opin Ther Targets. ' '2021;25:435–49.', 'journal-title': 'Expert Opin Ther Targets'}, { 'key': '1432_CR57', 'doi-asserted-by': 'crossref', 'first-page': '117', 'DOI': '10.1016/0014-2999(96)00254-3', 'volume': '307', 'author': 'N Narita', 'year': '1996', 'unstructured': 'Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interaction of selective ' 'serotonin reuptake inhibitors with subtypes of sigma receptors in rat ' 'brain. Eur J Pharm. 1996;307:117–9.', 'journal-title': 'Eur J Pharm'}, { 'key': '1432_CR58', 'doi-asserted-by': 'crossref', 'first-page': '8072', 'DOI': '10.1073/pnas.93.15.8072', 'volume': '93', 'author': 'M Hanner', 'year': '1996', 'unstructured': 'Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, ' 'et al. Purification, molecular cloning, and expression of the mammalian ' 'sigma1-binding site. Proc Natl Acad Sci USA. 1996;93:8072–7.', 'journal-title': 'Proc Natl Acad Sci USA'}, { 'key': '1432_CR59', 'doi-asserted-by': 'crossref', 'first-page': '596', 'DOI': '10.1016/j.cell.2007.08.036', 'volume': '131', 'author': 'T Hayashi', 'year': '2007', 'unstructured': 'Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion ' 'interface regulate Ca2+ signaling and cell survival. Cell. ' '2007;131:596–610.', 'journal-title': 'Cell'}, { 'key': '1432_CR60', 'doi-asserted-by': 'crossref', 'first-page': '557', 'DOI': '10.1517/14728222.2011.560837', 'volume': '15', 'author': 'T Hayashi', 'year': '2011', 'unstructured': 'Hayashi T, Tsai SY, Mori T, Fujimoto M, Su TP. Targeting ligand-operated ' 'chaperone sigma-1 receptors in the treatment of neuropsychiatric ' 'disorders. Expert Opin Ther Targets. 2011;15:557–77.', 'journal-title': 'Expert Opin Ther Targets'}, { 'key': '1432_CR61', 'doi-asserted-by': 'crossref', 'first-page': '1227', 'DOI': '10.1124/jpet.102.041970', 'volume': '303', 'author': 'M Takebayashi', 'year': '2002', 'unstructured': 'Takebayashi M, Hayashi T, Su TP. Nerve growth factor-induced neurite ' 'sprouting in PC12 cells involves sigma-1 receptors: implications for ' 'antidepressants. J Pharm Exp Ther. 2002;303:1227–37.', 'journal-title': 'J Pharm Exp Ther'}, { 'key': '1432_CR62', 'doi-asserted-by': 'crossref', 'first-page': 'e2558', 'DOI': '10.1371/journal.pone.0002558', 'volume': '3', 'author': 'T Nishimura', 'year': '2008', 'unstructured': 'Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth ' 'factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 ' 'receptors, IP3 receptors and cellular signaling pathways. PLoS ONE. ' '2008;3:e2558.', 'journal-title': 'PLoS ONE'}, { 'key': '1432_CR63', 'doi-asserted-by': 'crossref', 'first-page': '167', 'DOI': '10.1016/j.ejphar.2014.01.064', 'volume': '727', 'author': 'T Ishima', 'year': '2014', 'unstructured': 'Ishima T, Fujita Y, Hashimoto K. Interactions of new antidepressants ' 'with sigma-1 receptor chaperons and their potentiation of neurite ' 'outgrowth in PC12 cells. Eur J Pharm. 2014;727:167–73.', 'journal-title': 'Eur J Pharm'}, { 'key': '1432_CR64', 'doi-asserted-by': 'crossref', 'first-page': '878', 'DOI': '10.1016/j.biopsych.2007.04.001', 'volume': '62', 'author': 'M Ishikawa', 'year': '2007', 'unstructured': 'Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, et al. ' 'High occupancy of sigma-1 receptors in the human brain after single oral ' 'administration of fluvoxamine: a positron emission tomography using ' '[11C]SA4503. Biol Psychiatry. 2007;62:878–83.', 'journal-title': 'Biol Psychiatry'}, { 'key': '1432_CR65', 'doi-asserted-by': 'crossref', 'first-page': '193', 'DOI': '10.1002/hup.1106', 'volume': '25', 'author': 'I Hindmarch', 'year': '2010', 'unstructured': 'Hindmarch I, Hashimoto K. Cognition and depression: the effects of ' 'fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum ' 'Psychopharmacol. 2010;25:193–200.', 'journal-title': 'Hum Psychopharmacol'}, { 'key': '1432_CR66', 'doi-asserted-by': 'crossref', 'first-page': '875', 'DOI': '10.2174/138161212799436476', 'volume': '18', 'author': 'T Niitsu', 'year': '2012', 'unstructured': 'Niitsu T, Iyo M, Hashimoto K. Sigma-1 receptor agonists as therapeutic ' 'drugs for cognitive impairment in neuropsychiatric disorders. Curr Pharm ' 'Des. 2012;18:875–83.', 'journal-title': 'Curr Pharm Des'}, { 'key': '1432_CR67', 'doi-asserted-by': 'crossref', 'first-page': '6', 'DOI': '10.1016/j.jphs.2014.11.010', 'volume': '127', 'author': 'K Hashimoto', 'year': '2015', 'unstructured': 'Hashimoto K. Activation of sigma-1 receptor chaperone in the treatment ' 'of neuropsychiatric diseases and its clinical implication. J Pharm Sci. ' '2015;127:6–9.', 'journal-title': 'J Pharm Sci'}, { 'key': '1432_CR68', 'doi-asserted-by': 'crossref', 'first-page': '153', 'DOI': '10.1007/978-3-319-50174-1_11', 'volume': '964', 'author': 'Y Albayrak', 'year': '2017', 'unstructured': 'Albayrak Y, Hashimoto K. Sigma-1 receptor agonists and their clinical ' 'implication in neuropsychiatric disorders. Adv Exp Med Biol. ' '2017;964:153–61.', 'journal-title': 'Adv Exp Med Biol'}, { 'key': '1432_CR69', 'doi-asserted-by': 'crossref', 'first-page': 'eaau5266.', 'DOI': '10.1126/scitranslmed.aau5266', 'volume': '11', 'author': 'DA Rosen', 'year': '2019', 'unstructured': 'Rosen DA, Seki SM, Fernández-Castañeda A, Beiter RM, Eccles JD, Woodfolk ' 'JA, et al. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial ' 'in preclinical models of inflammation and sepsis. Sci Transl Med. ' '2019;11:eaau5266.', 'journal-title': 'Sci Transl Med'}, { 'key': '1432_CR70', 'doi-asserted-by': 'crossref', 'first-page': '15', 'DOI': '10.1016/j.pneurobio.2012.09.001', 'volume': '100', 'author': 'K Hashimoto', 'year': '2013', 'unstructured': 'Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic ' 'factor: emerging links between cardiovascular disease and depression. ' 'Prog Neurobiol. 2013;100:15–29.', 'journal-title': 'Prog Neurobiol'}, { 'key': '1432_CR71', 'doi-asserted-by': 'crossref', 'first-page': '152', 'DOI': '10.3389/fpubh.2020.00152', 'volume': '8', 'author': 'JM Jin', 'year': '2020', 'unstructured': 'Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender differences in ' 'patients with COVID-19: Focus on severity and mortality. Front Public ' 'Health. 2020;8:152.', 'journal-title': 'Front Public Health'}, { 'key': '1432_CR72', 'doi-asserted-by': 'crossref', 'first-page': '29.', 'DOI': '10.1186/s13293-020-00304-9', 'volume': '11', 'author': 'C Gebhard', 'year': '2020', 'unstructured': 'Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact ' 'of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. ' '2020;11:29.', 'journal-title': 'Biol Sex Differ'}, { 'key': '1432_CR73', 'doi-asserted-by': 'crossref', 'first-page': '1043', 'DOI': '10.1111/andr.12993', 'volume': '9', 'author': 'A Salonia', 'year': '2021', 'unstructured': 'Salonia A, Pontillo M, Capogrosso P, Gregori S, Tassara M, Boeri L, et ' 'al. Severely low testosterone in males with COVID-19: a case-control ' 'study. Andrology. 2021;9:1043–52.', 'journal-title': 'Andrology'}, { 'key': '1432_CR74', 'doi-asserted-by': 'crossref', 'first-page': 'e2111398', 'DOI': '10.1001/jamanetworkopen.2021.11398', 'volume': '4', 'author': 'S Dhindsa', 'year': '2021', 'unstructured': 'Dhindsa S, Zhang N, McPhaul MJ, Wu Z, Ghoshal AK, Erlich EC, et al. ' 'Association of circulating sex hormones with inflammation and disease ' 'severity in patients with COVID-19. JAMA Netw Open. 2021;4:e2111398.', 'journal-title': 'JAMA Netw Open'}, { 'key': '1432_CR75', 'doi-asserted-by': 'crossref', 'first-page': '694083.', 'DOI': '10.3389/fendo.2021.694083', 'volume': '12', 'author': 'L Lanser', 'year': '2021', 'unstructured': 'Lanser L, Burkert FR, Thommens L, Egger A, Hoermann G, Kaser S, et al. ' 'Testosterone deficiency is a risk factor for severe COVID-19. Front ' 'Endocrinol (Lausanne). 2021;12:694083.', 'journal-title': 'Front Endocrinol (Lausanne)'}, { 'key': '1432_CR76', 'doi-asserted-by': 'crossref', 'first-page': '100110', 'DOI': '10.1016/j.endmts.2021.100110', 'volume': '5', 'author': 'SB Shah', 'year': '2021', 'unstructured': 'Shah SB. COVID-19 and progesterone: Part 1. SARS-CoV-2, progesterone and ' 'its potential clinical use. Endcr Metab Sci. 2021;5:100110.', 'journal-title': 'Endcr Metab Sci'}, { 'key': '1432_CR77', 'doi-asserted-by': 'crossref', 'first-page': '100110', 'DOI': '10.1016/j.endmts.2021.100110', 'volume': '5', 'author': 'SB Shah', 'year': '2021', 'unstructured': 'Shah SB. COVID-19 and progesterone: Part 2. Unraveling high severity, ' 'immunity patterns, immunity grading, progesterone and its potential ' 'clinical use. Endcr Metab Sci. 2021;5:100110.', 'journal-title': 'Endcr Metab Sci'}, { 'key': '1432_CR78', 'doi-asserted-by': 'crossref', 'first-page': '74', 'DOI': '10.1016/j.chest.2021.02.024', 'volume': '160', 'author': 'S Ghandehari', 'year': '2021', 'unstructured': 'Ghandehari S, Matusov Y, Pepkowitz S, Stein D, Kaderi T, Narayanan D, et ' 'al. Progesterone in addition to standard of care vs standard of care ' 'alone in the treatment of men hospitalized with moderate to severe ' 'COVID-19: a randomized, controlled pilot trial. Chest. 2021;160:74–84.', 'journal-title': 'Chest'}, { 'key': '1432_CR79', 'doi-asserted-by': 'crossref', 'first-page': '514', 'DOI': '10.1038/sj.npp.1301047', 'volume': '32', 'author': 'K Hashimoto', 'year': '2007', 'unstructured': 'Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits ' 'in mice are improved by subsequent subchronic administration of ' 'fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology. ' '2007;32:514–21.', 'journal-title': 'Neuropsychopharmacology'}, { 'key': '1432_CR80', 'doi-asserted-by': 'crossref', 'first-page': '280', 'DOI': '10.33594/000000021', 'volume': '52', 'author': 'C Li', 'year': '2019', 'unstructured': 'Li C, Wang A, Wu Y, Gulbins E, Grassmé H, Zhao Z. Acid ' 'sphingomyelinase-ceramide system in bacterial infections. Cell Physiol ' 'Biochem. 2019;52:280–301.', 'journal-title': 'Cell Physiol Biochem'}, { 'key': '1432_CR81', 'doi-asserted-by': 'crossref', 'first-page': '5676', 'DOI': '10.3390/ijms22115676', 'volume': '22', 'author': 'N Beckmann', 'year': '2021', 'unstructured': 'Beckmann N, Becker KA. Ceramide and related molecules in viral ' 'infections. Int J Mol Sci. 2021;22:5676.', 'journal-title': 'Int J Mol Sci'}, { 'key': '1432_CR82', 'doi-asserted-by': 'crossref', 'first-page': '689854.', 'DOI': '10.3389/fcell.2021.689854', 'volume': '9', 'author': 'K Törnquist', 'year': '2021', 'unstructured': 'Törnquist K, Asghar MY, Srinivasan V, Korhonen L, Lindholm D. ' 'Sphingolipids as modulators of SARS-CoV-2 infection. Front Cell Dev ' 'Biol. 2021;9:689854.', 'journal-title': 'Front Cell Dev Biol'}, { 'key': '1432_CR83', 'doi-asserted-by': 'publisher', 'unstructured': 'Kornhuber J, Hoertel N, Gulbins E. The acid sphingomyelinase/ceramide ' 'system in COVID-19. Mol Psychiatry. 2021. ' 'https://doi.org/10.1038/s41380-021-01309-5.', 'DOI': '10.1038/s41380-021-01309-5'}, { 'key': '1432_CR84', 'doi-asserted-by': 'crossref', 'first-page': '9', 'DOI': '10.1159/000315101', 'volume': '26', 'author': 'J Kornhuber', 'year': '2010', 'unstructured': 'Kornhuber J, Tripal P, Reichel M, Mühle C, Rhein C, Muehlbacher M, et ' 'al. Functional inhibitors of acid sphingomyelinase (FIASMAs): a novel ' 'pharmacological group of drugs with broad clinical applications. Cell ' 'Physiol Biochem. 2010;26:9–20.', 'journal-title': 'Cell Physiol Biochem'}, { 'key': '1432_CR85', 'doi-asserted-by': 'crossref', 'first-page': '934', 'DOI': '10.1038/nm.3214', 'volume': '19', 'author': 'E Gulbins', 'year': '2013', 'unstructured': 'Gulbins E, Palmada M, Reichel M, Lüth A, Böhmer C, Amato D, et al. Acid ' 'sphingomyelinase-ceramide system mediates effects of antidepressant ' 'drugs. Nat Med. 2013;19:934–8.', 'journal-title': 'Nat Med'}, { 'key': '1432_CR86', 'doi-asserted-by': 'crossref', 'first-page': '2324', 'DOI': '10.1038/s41380-018-0090-9', 'volume': '23', 'author': 'A Gulbins', 'year': '2018', 'unstructured': 'Gulbins A, Schumacher F, Becker KA, Wilker B, Soddemann M, Boldrin F, et ' 'al. Antidepressants act by inducing autophagy controlled by ' 'sphingomyelin-ceramide. Mol Psychiatry. 2018;23:2324–46.', 'journal-title': 'Mol Psychiatry'}, { 'key': '1432_CR87', 'doi-asserted-by': 'crossref', 'first-page': '100142', 'DOI': '10.1016/j.xcrm.2020.100142', 'volume': '1', 'author': 'A Carpinteiro', 'year': '2020', 'unstructured': 'Carpinteiro A, Edwards MJ, Hoffmann M, Kochs G, Gripp B, Weigang S, et ' 'al. Pharmacological inhibition of acid sphingomyelinase prevents uptake ' 'of SARS-CoV-2 by epithelial cells. Cell Rep Med. 2020;1:100142.', 'journal-title': 'Cell Rep Med'}, { 'key': '1432_CR88', 'doi-asserted-by': 'crossref', 'first-page': '691.', 'DOI': '10.3390/ph14070691', 'volume': '14', 'author': 'G Loas', 'year': '2021', 'unstructured': 'Loas G, Le Corre P. Update on functional inhibitors of acid ' 'sphingomyelinase (FISMAs) in SARS-CoV-2 infection. Pharm (Basel). ' '2021;14:691.', 'journal-title': 'Pharm (Basel)'}, { 'key': '1432_CR89', 'doi-asserted-by': 'crossref', 'first-page': 'e23852', 'DOI': '10.1371/journal.pone.0023852', 'volume': '6', 'author': 'J Kornhuber', 'year': '2011', 'unstructured': 'Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, et ' 'al. Identification of novel functional inhibitors of acid ' 'sphingomyelinase. PLoS ONE. 2011;6:e23852.', 'journal-title': 'PLoS ONE'}, { 'key': '1432_CR90', 'doi-asserted-by': 'crossref', 'first-page': '1498', 'DOI': '10.1002/cpt.2317', 'volume': '110', 'author': 'N Hoertel', 'year': '2021', 'unstructured': 'Hoertel N, Sánchez-Rico M, Gulbins E, Kornhuber J, Carpinteiro A, Lenze ' 'EJ, et al. Association between FIASMAs and reduced risk of intubation or ' 'death in individuals hospitalized for severe COVID-19: an observational ' 'multicenter study. Clin Pharm Ther. 2021;110:1498–511.', 'journal-title': 'Clin Pharm Ther'}, { 'key': '1432_CR91', 'doi-asserted-by': 'crossref', 'first-page': '106274', 'DOI': '10.1016/j.ijantimicag.2020.106274', 'volume': '57', 'author': 'M Plaze', 'year': '2021', 'unstructured': 'Plaze M, Attali D, Prot M, Petit AC, Blatzer M, Vinckier F, et al. ' 'Inhibition of the replication of SARS-CoV-2 in human cells by the ' 'FDA-approved drug chlorpromazine. Int J Antimicrob Agents. ' '2021;57:106274.', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': '1432_CR92', 'doi-asserted-by': 'publisher', 'unstructured': 'Hoertel N, Sánchez-Rico M, Cougoule C, Gulbins E, Kornhuber J, ' 'Carpinteiro A, et al. Repurposing antidepressants inhibiting the ' 'sphingomyelinase acid/ceramide system against COVID-19: current evidence ' 'and potential mechanisms. Mol Psychiatry. 2021. ' 'https://doi.org/10.1038/s41380-021-01254-3.', 'DOI': '10.1038/s41380-021-01254-3'}, { 'key': '1432_CR93', 'doi-asserted-by': 'crossref', 'first-page': '117583.', 'DOI': '10.1016/j.lfs.2020.117583', 'volume': '250', 'author': 'R Zhang', 'year': '2020', 'unstructured': 'Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al. COVID-19: Melatonin as ' 'a potential adjunct treatment. Life Sci. 2020;250:117583.', 'journal-title': 'Life Sci'}, { 'key': '1432_CR94', 'doi-asserted-by': 'crossref', 'first-page': 'e2109.', 'DOI': '10.1002/rmv.2109', 'volume': '30', 'author': 'G Anderson', 'year': '2020', 'unstructured': 'Anderson G, Reiter RJ. Melatonin: roles in influenza, Covid-19, and ' 'other infections. Rev Med Virol. 2020;30:e2109.', 'journal-title': 'Rev Med Virol'}, { 'key': '1432_CR95', 'doi-asserted-by': 'crossref', 'first-page': '611', 'DOI': '10.1007/s00213-020-05753-z', 'volume': '238', 'author': 'GM Anderson', 'year': '2021', 'unstructured': 'Anderson GM. Fluvoxamine, melatonin and COVID-19. Psychopharmacology. ' '2021;238:611.', 'journal-title': 'Psychopharmacology'}, { 'key': '1432_CR96', 'doi-asserted-by': 'crossref', 'first-page': '483', 'DOI': '10.1080/14787210.2017.1305888', 'volume': '15', 'author': 'C Salata', 'year': '2017', 'unstructured': 'Salata C, Calistri A, Parolin C, Baritussio A, Palù G. Antiviral ' 'activity of cationic amphiphilic drugs. Expert Rev Anti Infect Ther. ' '2017;15:483–92.', 'journal-title': 'Expert Rev Anti Infect Ther'}, { 'key': '1432_CR97', 'doi-asserted-by': 'crossref', 'first-page': '787261', 'DOI': '10.3389/fphar.2021.787261', 'volume': '21', 'author': 'OO Glebov', 'year': '2021', 'unstructured': 'Glebov OO. Low-dose fluvoxamine modulates endocytic trafficking of ' 'SARS-CoV-2 spike protein: a potential mechanism for anti-COVID-19 ' 'protection by antidepressants. Front Pharmacol. 2021;21:787261.', 'journal-title': 'Front Pharmacol'}, { 'key': '1432_CR98', 'doi-asserted-by': 'crossref', 'unstructured': 'Fred SM, Kuivanen S, Ugurlu H, Casarotto PC, Levanov L, Saksela K, et ' 'al. Antidepressant and antipsychotic drugs reduce viral infection by ' 'SARS-CoV-2 and fluoxetine show antiviral activity against the novel ' 'variants in vitro. bioRxiv 10.110/2021.03.22.436379 [Preprint].', 'DOI': '10.1101/2021.03.22.436379'}, { 'key': '1432_CR99', 'doi-asserted-by': 'crossref', 'first-page': '284', 'DOI': '10.1093/schbul/sbq146', 'volume': '37', 'author': 'AS Brown', 'year': '2011', 'unstructured': 'Brown AS, Patterson PH. Maternal infection and schizophrenia: ' 'implications for prevention. Schizophr Bull. 2011;37:284–90.', 'journal-title': 'Schizophr Bull'}, { 'key': '1432_CR100', 'doi-asserted-by': 'crossref', 'first-page': '389', 'DOI': '10.1016/j.molmed.2011.03.001', 'volume': '17', 'author': 'PH Patterson', 'year': '2011', 'unstructured': 'Patterson PH. Maternal infection and immune involvement in autism. ' 'Trends Mol Med. 2011;17:389–94.', 'journal-title': 'Trends Mol Med'}, { 'key': '1432_CR101', 'doi-asserted-by': 'crossref', 'first-page': '1073', 'DOI': '10.1176/appi.ajp.2018.17121311', 'volume': '175', 'author': 'AS Brown', 'year': '2018', 'unstructured': 'Brown AS, Meyer U. Maternal immune activation and neuropsychiatric ' 'illness: a translational research perspective. Am J Psychiatry. ' '2018;175:1073–83.', 'journal-title': 'Am J Psychiatry'}, { 'key': '1432_CR102', 'doi-asserted-by': 'crossref', 'first-page': '774', 'DOI': '10.1001/archpsyc.61.8.774', 'volume': '61', 'author': 'AS Brown', 'year': '2004', 'unstructured': 'Brown AS, Begg MD, Gravenstein S, Schaefer CA, Wyatt RJ, Bresnahan M, et ' 'al. Serologic evidence of prenatal influenza in the etiology of ' 'schizophrenia. Arch Gen Psychiatry. 2004;61:774–80.', 'journal-title': 'Arch Gen Psychiatry'}, { 'key': '1432_CR103', 'doi-asserted-by': 'crossref', 'first-page': '1423', 'DOI': '10.1007/s10803-010-1006-y', 'volume': '40', 'author': 'HO Atladóttir', 'year': '2010', 'unstructured': 'Atladóttir HO, Thorsen P, Østergaard L, Schendel DE, Lemcke S, Abdallah ' 'M, et al. maternal infection requiring hospitalization during pregnancy ' 'and autism spectrum disorders. J Autism Dev Disord. 2010;40:1423–30.', 'journal-title': 'J Autism Dev Disord'}, { 'key': '1432_CR104', 'doi-asserted-by': 'crossref', 'first-page': '573468', 'DOI': '10.3389/fmed.2020.573468', 'volume': '7', 'author': 'MM Islam', 'year': '2020', 'unstructured': 'Islam MM, Poly TN, Walther BA, Yang HC, Wang CW, Hsieh WS, et al. ' 'Clinical characteristics and neonatal outcomes of pregnant patients with ' 'COVID-19: a systematic review. Front Med. 2020;7:573468.', 'journal-title': 'Front Med'}, { 'key': '1432_CR105', 'doi-asserted-by': 'crossref', 'first-page': '155431', 'DOI': '10.1016/j.cyto.2021.155431', 'volume': '140', 'author': 'A Tanacan', 'year': '2021', 'unstructured': 'Tanacan A, Yazihan N, Erol SA, Anuk AT, Yetiskin FDY, Burken D, et al. ' 'The impact of COVID-19 infection on the cytokine profile of pregnant ' 'women: a prospective case-control study. Cytokine. 2021;140:155431.', 'journal-title': 'Cytokine'}, { 'key': '1432_CR106', 'doi-asserted-by': 'crossref', 'first-page': '299', 'DOI': '10.1007/978-3-030-59261-5_27', 'volume': '1321', 'author': 'S Makvandi', 'year': '2021', 'unstructured': 'Makvandi S, Mahdavian M, Kazemi-Nia G, Vahedian-Azimi A, Guest PC, ' 'Karimi L, et al. The 2019 novel coronavirus disease in pregnancy: a ' 'systematic review. Adv Exp Med Biol. 2021;1321:299–307.', 'journal-title': 'Adv Exp Med Biol'}, { 'key': '1432_CR107', 'doi-asserted-by': 'crossref', 'first-page': 'e0253974.', 'DOI': '10.1371/journal.pone.0253974', 'volume': '16', 'author': 'A Ciapponi', 'year': '2021', 'unstructured': 'Ciapponi A, Bardach A, Comandé D, Berrueda M, Argento FJ, Cairoli FR, et ' 'al. COVID-19 and pregnancy: an umbrella review of clinical presentation, ' 'vertical transmission, and maternal and perinatal outcomes. PLoS ONE. ' '2021;16:e0253974.', 'journal-title': 'PLoS ONE'}, { 'key': '1432_CR108', 'doi-asserted-by': 'crossref', 'first-page': '817', 'DOI': '10.1001/jamapediatrics.2021.1050', 'volume': '175', 'author': 'J Villar', 'year': '2021', 'unstructured': 'Villar J, Ariff S, Gunier RB, Thiruvengadam R, Rauch S, Kholin A, et al. ' 'Maternal and neonatal morbidity and mortality among pregnant women with ' 'and without COVID-19 infection: the INTERCOVID multinational cohort ' 'study. JAMA Pediatr. 2021;175:817–26.', 'journal-title': 'JAMA Pediatr'}, { 'key': '1432_CR109', 'doi-asserted-by': 'crossref', 'first-page': '2273', 'DOI': '10.1056/NEJMoa2104983', 'volume': '384', 'author': 'TT Shimabukuro', 'year': '2021', 'unstructured': 'Shimabukuro TT, Kim SY, Meyers TR, Moro PL, Oduyebo T, Panagiotakopoulos ' 'L, et al. Preliminary findings of mRNA Covid-19 vaccine safety in ' 'pregnant persons. N. Eng J Med. 2021;384:2273–82.', 'journal-title': 'N. Eng J Med'}, { 'key': '1432_CR110', 'volume': '8', 'author': 'A Matsuura', 'year': '2018', 'unstructured': 'Matsuura A, Ishima T, Fujita Y, Iwayama Y, Hasegawa S, Kawahara-Miki R, ' 'et al. Dietary glucoraphanin prevents the onset of psychosis in the ' 'adult offspring after maternal immune activation. Sci Rep. 2018;8:2158.', 'journal-title': 'Sci Rep.'}, { 'key': '1432_CR111', 'doi-asserted-by': 'crossref', 'first-page': '268', 'DOI': '10.1002/npr2.12112', 'volume': '40', 'author': 'Y Fujita', 'year': '2020', 'unstructured': 'Fujita Y, Fujita A, Ishima T, Hirai A, Suzuki S, Suganuma H, et al. ' 'Dietary intake of glucoraphanin during pregnancy and lactation prevents ' 'the behavioral abnormalities in the offspring after maternal immune ' 'activation. Neuropsychopharmacol Rep. 2020;40:268–74.', 'journal-title': 'Neuropsychopharmacol Rep.'}, { 'key': '1432_CR112', 'doi-asserted-by': 'crossref', 'DOI': '10.1007/s11920-019-1063-7', 'volume': '21', 'author': 'K Hashimoto', 'year': '2019', 'unstructured': 'Hashimoto K. Recent advances in the early intervention in schizophrenia: ' 'future direction from preclinical findings. Curr Psychiatry Rep. ' '2019;21:75.', 'journal-title': 'Curr Psychiatry Rep.'}, { 'key': '1432_CR113', 'doi-asserted-by': 'crossref', 'first-page': '387', 'DOI': '10.1007/s00406-020-01148-5', 'volume': '271', 'author': 'K Hashimoto', 'year': '2021', 'unstructured': 'Hashimoto K. Risk of neuropsychiatric disorders in offspring of ' 'COVID-19-infected pregnant women and nutritional intervention. Eur Arch ' 'Psychiatry Clin Neurosci. 2021;271:387–9.', 'journal-title': 'Eur Arch Psychiatry Clin Neurosci'}, { 'key': '1432_CR114', 'doi-asserted-by': 'crossref', 'first-page': '118', 'DOI': '10.1002/ped4.12199', 'volume': '4', 'author': 'Y Li', 'year': '2020', 'unstructured': 'Li Y, Freedman R. Prospects for improving future mental health of ' 'children through prenatal maternal micronutrient supplementation in ' 'China. Pediatr Investig. 2020;4:118–26.', 'journal-title': 'Pediatr Investig'}, { 'key': '1432_CR115', 'doi-asserted-by': 'crossref', 'first-page': '100297.', 'DOI': '10.1016/j.bbih.2021.100297', 'volume': '16', 'author': 'B Lins', 'year': '2021', 'unstructured': 'Lins B. Maternal immune activation as a risk factor for psychiatric ' 'illness in the context of the SARS-CoV-2 pandemic. Brain Behav Immun ' 'Health. 2021;16:100297.', 'journal-title': 'Brain Behav Immun Health'}, { 'key': '1432_CR116', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1016/j.clnesp.2021.04.019', 'volume': '43', 'author': 'MC Hoffman', 'year': '2021', 'unstructured': 'Hoffman MC, Freedman R, Law AJ, Clark AM, Hunter SK. Maternal nutrients ' 'and effects of gestational COVID-19 infection on fetal brain ' 'development. Clin Nutr ESPEN. 2021;43:1–8.', 'journal-title': 'Clin Nutr ESPEN'}, { 'key': '1432_CR117', 'doi-asserted-by': 'crossref', 'first-page': '161', 'DOI': '10.1016/j.eurpsy.2017.06.001', 'volume': '45', 'author': 'S Andalib', 'year': '2017', 'unstructured': 'Andalib S, Emamhadi MR, Yousefzadeh-Chabok S, Shakouri SK, ' 'Høilund-Carlsen PF, Vafaee MS, et al. Maternal SSRI exposure increases ' 'the risk of autistic offspring: a meta-analysis and systematic review. ' 'Eur Psychiatry. 2017;45:161–6.', 'journal-title': 'Eur Psychiatry'}, { 'key': '1432_CR118', 'doi-asserted-by': 'crossref', 'first-page': '555', 'DOI': '10.1001/jamapediatrics.2017.0124', 'volume': '171', 'author': 'A Mezzacappa', 'year': '2017', 'unstructured': 'Mezzacappa A, Lasica PA, Gianfagna F, Cazas O, Hardy P, Falissard B, et ' 'al. Risk for autism spectrum disorders according to period of prenatal ' 'antidepressant exposure: a systematic review and meta-analysis. JAMA ' 'Pediatr. 2017;171:555–63.', 'journal-title': 'JAMA Pediatr'}, { 'key': '1432_CR119', 'doi-asserted-by': 'crossref', 'first-page': '1553', 'DOI': '10.1001/jama.2017.3413', 'volume': '317', 'author': 'AC Sujan', 'year': '2017', 'unstructured': 'Sujan AC, Rickert ME, Öberg AS, Quinn PD, Hernández-Díaz S, Almqvist C, ' 'et al. Associations of maternal antidepressant use during the first ' 'trimester of pregnancy with preterm birth, small for gestational age, ' 'autism spectrum disorder, and attention-deficit/hyperactivity disorder ' 'in offspring. JAMA. 2017;317:1553–62.', 'journal-title': 'JAMA'}, { 'key': '1432_CR120', 'doi-asserted-by': 'crossref', 'first-page': '1241', 'DOI': '10.1001/jamapsychiatry.2019.2859', 'volume': '76', 'author': 'E Dragioti', 'year': '2019', 'unstructured': 'Dragioti E, Solmi M, Favaro A, Fusar-Poli P, Dazzan P, Thompson T, et ' 'al. Association of antidepressant use with adverse health outcomes: a ' 'systematic umbrella review. JAMA Psychiatry. 2019;76:1241–55.', 'journal-title': 'JAMA Psychiatry'}, { 'key': '1432_CR121', 'doi-asserted-by': 'crossref', 'first-page': '506', 'DOI': '10.1176/appi.ajp.2020.18070766', 'volume': '177', 'author': 'ML Vega', 'year': '2020', 'unstructured': 'Vega ML, Newport GC, Bozhdaraj D, Saltz SB, Nemeroff CB, Newport DJ. ' 'Implementation of advanced methods for reproductive pharmacovigilance in ' 'autism: a meta-analysis of the effects of prenatal antidepressant ' 'exposure. Am J Psychiatry. 2020;177:506–17.', 'journal-title': 'Am J Psychiatry'}, { 'key': '1432_CR122', 'doi-asserted-by': 'crossref', 'first-page': '113912', 'DOI': '10.1016/j.psychres.2021.113912', 'volume': '300', 'author': 'LM Tomfohr-Madsen', 'year': '2021', 'unstructured': 'Tomfohr-Madsen LM, Racine N, Giesbrecht GF, Lebel C, Madigan S. ' 'Depression and anxiety in pregnancy during COVID-19: A rapid review and ' 'meta-analysis. Psychiatry Res. 2021;300:113912.', 'journal-title': 'Psychiatry Res'}, { 'key': '1432_CR123', 'first-page': 'CD013825', 'volume': '9', 'author': 'N Kreuzberger', 'year': '2021', 'unstructured': 'Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, et ' 'al. SARS-CoV-2-neutralising monoclonal antibodies for treatment of ' 'COVID-19. Cochrane Database Syst Rev. 2021;9:CD013825.', 'journal-title': 'Cochrane Database Syst Rev'}, { 'key': '1432_CR124', 'doi-asserted-by': 'crossref', 'first-page': 'n2422.', 'DOI': '10.1136/bmj.n2422', 'volume': '375', 'author': 'E Mahase', 'year': '2021', 'unstructured': 'Mahase E. Covid-19: molnupiravir reduces risk of hospital admission or ' 'death by 50% in patients at risk, MSD reports. BMJ. 2021;375:n2422.', 'journal-title': 'BMJ'}, { 'key': '1432_CR125', 'doi-asserted-by': 'publisher', 'unstructured': 'Sidik SM. Common antidepressant slashes risk of COVID-19 death. Nature. ' '2021. https://doi.org/10.1038/d41586-021-02988-4.', 'DOI': '10.1038/d41586-021-02988-4'}], 'container-title': ['Molecular Psychiatry'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.nature.com/articles/s41380-021-01432-3.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41380-021-01432-3', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41380-021-01432-3.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 1, 7]], 'date-time': '2022-01-07T11:06:11Z', 'timestamp': 1641553571000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 1, 7]]}, 'references-count': 125, 'alternative-id': ['1432'], 'URL': 'http://dx.doi.org/10.1038/s41380-021-01432-3', 'relation': {}, 'ISSN': ['1359-4184', '1476-5578'], 'issn-type': [{'value': '1359-4184', 'type': 'print'}, {'value': '1476-5578', 'type': 'electronic'}], 'subject': ['Cellular and Molecular Neuroscience', 'Psychiatry and Mental health', 'Molecular Biology'], 'published': {'date-parts': [[2022, 1, 7]]}, 'assertion': [ { 'value': '4 October 2021', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '13 December 2021', 'order': 2, 'name': 'revised', 'label': 'Revised', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '23 December 2021', 'order': 3, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '7 January 2022', 'order': 4, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': 'Dr. Y. Hashimoto and Dr. T. Suzuki have no conflict of interest. Dr. K. ' 'Hashimoto is the inventor of filed patent applications on “The use of ' '<i>R</i>-Ketamine in the treatment of psychiatric diseases”, ' '“(<i>S</i>)-norketamine and salt thereof as pharmaceutical”, “<i>R</i>-Ketamine ' 'and derivative thereof as a prophylactic or therapeutic agent for ' 'neurodegeneration disease or recognition function disorder”, “Preventive or ' 'therapeutic agent and pharmaceutical composition for inflammatory diseases or ' 'bone diseases”, and “<i>R</i>-Ketamine and its derivatives as a preventive or ' 'therapeutic agent for a neurodevelopmental disorder” by the Chiba University. ' 'Dr. K. Hashimoto has also received speakers’ honoraria, consultant fees, or ' 'research support from Abbott, Meiji Seika Pharma, Dainippon-Sumitomo, Taisho, ' 'Otsuka, Murakami Farm, and Perception Neuroscience.', 'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Conflict of interest'}}, { 'value': 'This content has been made available to all.', 'name': 'free', 'label': 'Free to read'}]}